Table 1.

Descriptive data of the studies included in the meta-analysis.

	Al-Majid et al. [32]	Courneya et al. [33]	Jones et al. [22]	Kim et al. [34]	Lee et al. [24]	Ma [23]	Mijwel et al. [29]	Moller et al. [30]	Mowafy et al. [31]
PUBLICATION YEAR	2015	2007	2013	2006	2019	2018	2018	2015	2016
AGE
USUAL CARE	52.7 ± 10.7	49	46 ± 11	48.3 ± 8.8	44.7 ± 11.2	43.5 ± 6.3	52.6 ± 10.2	46.95 ± 9.19	45
TRAINING	47.9 ± 10.4	49	51 ± 6	51.3 ± 6.7	49.1 ± 7.9	44.2 ± 5.7	54.4 ± 10.3	48.49 ± 8.41	45
(N)
USUAL CARE	7	73	10	19	15	33	51	10	20
TRAINING	6	71	10	22	15	31	70	10	20
CHEMOTHERAPY
NEO			Y		Y
ADJ	Y	Y		Y	Y	Y	Y	Y	Y
TYPE
NON TAX
AC		Y	Y	Y	Y	Y	Y	Y
CYC			Y					Y
FE100C, CE120F		Y
TRAST
TAXANE		Y		Y			Y	Y
TRAINING PROTOCOL
DURATION (weeks)	12	18	12	8	8	16	16	12	16
MODE	CON	CON	CON	CON	INT	INT	CON	CON	CON
VOLUME MEAN (min/week)	90	97.5	102	90	63	150	60	150	45
INTENSITY	VIG	VIG	MOD	VIG	VIG	VIG	VIG	MOD	VIG
TIME (min) × INTENSITY
LIGHT					336				-
MODERATE	130	315	795			574		1800	-
VIGOROUS	1050	1170	400	720		960	802		-
MAXIMAL			30		168
VO2 OUTCOMES
USUAL CARE
PRE	23.8 ± 2.9 *	24.8 ± 6.2 *	17.5 ± 4.8 *	1597 ± 357 †	18.7 ± 7.1 *	1210 ± 258 †	2.19 ± 0.53 ‡	30.5 ± 5.0 *	21.1 ± 2.5 *
POST	17.5 ± 2.8	23.5 ± 5.4	16.0 ± 4.0	1630 ± 351	16.1 ± 6.0	984 ± 157	1.94 ± 0.52	27.7 ± 6.8	21.0 ± 2.4
TRAINING
PRE	26.1 ± 2.6	25.2 ± 7.2	19.5 ± 7.6	1671 ± 349	19.7 ± 8.7	1134 ± 268	2.10 ± 0.47	27.1 ± 6.4	21 ± 2.5
POST	26.0 ± 2.5	25.7 ± 7.4	22.1 ± 7.0	1810 ± 369	19.4 ± 6.6	1594 ± 190	2.06 ± 0.45	22.4 ± 6.5	30.8 ± 3.5

NEO = neoadjuvant; ADJ = adjuvant; TAX = taxane; AC = anthracycline; CYC = cyclophosphamide; TRAST = trastuzumab; CON = continuous; INT = interval; VIG = vigorous; MOD = moderate. LIGHT = 37–45% of VO_2max; MODERATE = 46–63% of VO_2max; VIGOROUS = 64–90% of VO_2max; MAXIMAL = ≥91% of VO_2max. * Unit: mL·kg⁻¹·min⁻¹; † mL·min⁻¹; ‡ L·min⁻¹. It was not possible to identify the time that was performed at each training intensity; however, as the training was performed until exhaustion, it was classified as vigorous.